Synjardy XR (empagliflozin/metformin ext rel) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTOR (if different than prescriber)**:**	**OFFICE CONTACT PERSON:**

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** **IF RENEWAL:** DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.

Synjardy XR (empagliflozin/metformin ext rel) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ YES (if yes, complete below) ☐ NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	**DURATION OF THERAPY** (SPECIFY DATES):	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
☐ Type II diabetes ☐ Type II diabetes with established cardiovascular disease ☐ Type II diabetes with Congestive heart failure ☐ Chronic kidney disease ☐ Other Diagnosis:_____ICD-10 Code(s):_____	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Clinical information:

For patients with Type II diabetes, please answer the following:

Is the patient's estimated glomerular filtration rate (eGFR) below 20 mL/min/1.73 m2? ☐ Yes ☐ No
Please provide documentation.

Is the patient's most recent (pre-SynjardyXR) HgbA1C obtained in the past 6 months 7% or greater prior to therapy (HbA1c must be taken within the past 6 months if the patient has not been on this treatment previously)? ☐ Yes ☐ No *Please provide documentation*

Is the patient on dialysis? ☐ Yes ☐ No

Is the patient currently on metformin?* ☐ Yes ☐ No

Does the patient had an inadequate response or intolerance to metform? ☐ Yes ☐ No *Provide documentation*

For patients with Type II diabetes with established cardiovascular disease, please answer the following:
Is the patient's most recent hemoglobin A1c level within the past 6months 7.0-10%, inclusive prior to therapy (HbA1c must be taken within the past 6 months if the patient has not been on this treatment previously)?
☐ Yes ☐ No *Please provide documentation.*

Does the patient's body mass index(BMI) exceed 45kg/m² ? ☐ Yes ☐ No

Is the patient's estimated glomerular filtration rate (eGFR) above 20 mL/min/1.73 m2? ☐ Yes ☐ No
Please provide documentation.

Is the patient's medical history positive for at least one of the following ? ☐ Yes ☐ No

Please check at least one of the following:
☐ MI or Stroke
☐ Imaging shows single-vessel or multi-vessel coronary artery disease
☐ Previous coronary revascularization procedure

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

□ **Positive cardiac stress test**
□ **Hospital admission for unstable angina**
□ **Occulsive peripheral arterial disease (defined as limb revascularization procedure, limb or foot amputation due to circulatory insufficiency, imaging or non-invasive study showing evidence of more than 50% stenosis in an artery, and/or ankle: brachial index equaling less than 0.9 in an ankle.)**

For diagnosis of Type II diabetes with congestive heart failure, please answer the following:
Does patient have an ejection fraction(EF) equaling 40% or less? □ Yes □ No ***Please provide documentation.***

Does patient have an ejection fraction(EF) greater than 40%? ***Please provide documentation.***

Has patient ever had NYHA class II, III or IV symptoms of heart failure? □ Yes □ No ***Please provide documentation.***

Does patient's body mass index(BMI) equal less than 45 kg/m² ? □ Yes □ No ***Please provide documentation.***

Does patient have a NT-proBNP greater than 300 pg/ml? □ Yes □ No ***Please provide documentation.***

For patients with A-fib, is the NT-proBNP greater than 900 pg/ml? □ Yes □ No ***Please provide documentation.***

IF NT-proBNP not available, does patient have a BNP >100 pg/ml without kidney failure? □ Yes □ No ***Please submit chart documentation.***

If NT-proBNP not available and patient has kidney failure, does patient have a BNP >200 pg/ml? □ Yes □ No ***Please submit chart documentation.***

If NT-proBNP not available and patient has Atrial fibrillation(AF), does patient have a BNP >150 pg/ml? □ Yes □ No ***Please submit chart documentation***

Does the patient have structural heart disease such as one or more of the following:? □ Yes □ No ***Please provide documentation from echocardiogram.***
□ **LA width > 4.0 cm**
□ **LA length > 5.0 cm**
□ **LA area > 20 cm2**
□ **LA volume > 55 ml**
□ **LA volume index > 34 ml/m2**
Does the patient has left ventricular hypertrophy defined by at least one of the following:? □ Yes □ No ***Please provide documentation from echocardiogram.***
□ **Septal thickness or posterior wall thickness >1.1 cm**
□ **LV mass index(LVMI) > 115 g/m2 for males and >95 g/m2 for females**
□ **E/e´ (mean septal and lateral) > 13**
□ **e´ (mean septal and lateral) < 9 cm/s**

Has patient been hospitalized in the past 12 months before starting Synjardy XR (empagliflozin/metformin)? □ Yes □ No ***Please provide documentation.***

Is patient on a stable dose of a diuretic? □ Yes □ No ***Please provide documentation.***

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Has patient had a myocardial infarction, coronary bypass graft surgery or other major cardiovascular surgery, stroke or TIA in the past 90 days of starting Jardiance? □ Yes □ No *Please provide documentation.*

Has patient had a heart translplant? □ Yes □ No

Does patient have acute decompensated heart failure? □ Yes □ No

Does patient have severe <u>pulmonary disease</u> including severe COPD, requiring home oxygen therapy for their COPD, chronic nebulizer therapy or chronic oral steroid therapy for treatment of their severe COPD? □ Yes □ No *Please submit chart documentation.*

Does patient have severe <u>pulmonary disease</u> including primary pulmonary hypertension? □ Yes □ No *Please submit chart documentation.*

Does patient have any other condition or diagnosis causing patient's heart failure symptoms such as patient has significant mitral valve regurgitation causing the heart failure, any dilated cardiomyopathy, infiltrative cardiomyopathy, drug induced cardiomyopathy, or viral myocarditis? □ Yes □ No *Please submit chart documentation.*

Does patient have and eGFR less than 20ml/min/1.73m^2? □ Yes □ No

Does patient require dialysis? □ Yes □ No

Is patient's heart failure related to any of the following? □ Yes □ No Please check at least one of the following:
□ infiltrative disease
□ accumulation disease
□ muscular dystrophy
□ hypertrophic obstructive cardiomyopathy
□ known pericardial restriction
□ valvular disease expected to lead to surgery
□ atrial fib/flutter with a resting heart rate greater than 110 bpm

<u>If prescribing for the diagnosis of chronic kidney disease(CKD), please answer the following</u>:
Does the patient have an estimated glomerular filtration rate(eGFR) ≥20 to <45 mL/min/1.73m^2 ? □ Yes □ No *Please submit chart documentation.*

Does the patient have an estimated glomerular filtration rate(eGFR) an eGFR ≥45 to <90 mL/min/1.73m^2 ? □ Yes □ No *Please submit chart documentation.*

Does patient have a urinary albumin:creatinine ratio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g)? □ Yes □ No *Please submit chart documentation.*

Is patient taking either a renin-angiotensin-converting enzyme inhibitor(ACEi) or or an angiotensin II receptor blocker(ARB)? □ Yes □ No *Please submit chart documentation.*
Is an ACEi or ARB contraindicated? □ Yes □ No *Please submit chart documentation.*

Synjardy XR (empagliflozin/metformin ext rel) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Does patient have TypeII diabetes AND prior atherosclerotic cardiovascular disease with an cGFR >60ml/min/1.73m² ? □ **Yes** □ **No** ***Please submit chart documentation.***

Is patient receiving both an ACEi and an ARB at the same time? □ **Yes** □ **No**

Is patient receiving maintenance dialysis? □ **Yes** □ **No**

Has the patient received a kidney transplant? □ **Yes** □ **No**

Does patient have polycystic kidney disease? □ **Yes** □ **No**

Does patient have Type1 diabetes? □ **Yes** □ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program
Attn: CP – 4201
P.O. Box 64811
St. Paul, MN 55164-0811